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Abstract: This work aimed to develop a new therapeutic approach to increase the efficacy 
of 5-fluorouracil (5-FU) in the treatment of advanced or recurrent colon cancer. 5-FU-loaded 
biodegradable poly(ε-caprolactone) nanoparticles (PCL NPs) were combined with the cytotoxic 
suicide gene E (combined therapy). The SW480 human cancer cell line was used to assay the 
combined therapeutic strategy. This cell line was established from a primary adenocarcinoma 
of the colon and is characterized by an intrinsically high resistance to apoptosis that correlates 
with its resistance to 5-FU. 5-FU was absorbed into the matrix of the PCL NPs during synthesis 
using the interfacial polymer disposition method. The antitumor activity of gene E from the phage 
φX174 was tested by generating a stable clone (SW480/12/E). In addition, the localization of 
E protein and its activity in mitochondria were analyzed. We found that the incorporation of 5-FU 
into PCL NPs (which show no cytotoxicity alone), significantly improved the drug’s anticancer 
activity, reducing the proliferation rate of colon cancer cells by up to 40-fold when compared 
with the nonincorporated drug alone. Furthermore, E gene expression sensitized colon cancer 
cells to the cytotoxic action of the 5-FU-based nanomedicine. Our findings demonstrate that 
despite the inherent resistance of SW480 to apoptosis, E gene activity is mediated by an apoptotic 
phenomenon that includes modulation of caspase-9 and caspase-3 expression and intense 
mitochondrial damage. Finally, a strongly synergistic antiproliferative effect was observed in 
colon cancer cells when E gene expression was combined with the activity of the 5-FU-loaded 
PCL NPs, thereby indicating the potential therapeutic value of the combined therapy.
Keywords: colon cancer, combined therapy, 5-fluorouracil, gene therapy, E gene, poly 
(ε-caprolactone)
Introduction
Colorectal cancer is the third most frequently diagnosed malignancy in the world. 
The annual incidence of colon cancer is estimated to be around one million, with 
approximately 500,000 patients dying from the disease each year.1 Recent advances in 
chemotherapy (including the use of irinotecan, oxaliplatin, and fluoropyrimidines, as 
well as cetuximab and bevacizumab) and radiation therapy have increased the median 
survival of patients. However, advanced or recurrent colon cancer remains incurable 
by conventional treatments,2 therefore more effective treatment options are needed 
for the treatment of this disease.
Despite the efficacy of 5-fluorouracil (5-FU) against a wide variety of tumors,3 
this antitumor molecule suffers from several drawbacks. As a consequence of a very 
rapid in vivo metabolism, 5-FU has a short biological half-life. Furthermore, the drug 
displays nonuniform oral absorption (with significant patient-to-patient variations in 
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bioavailability), and tumor cells often undergo significant 
development of drug resistance. These characteristics lead 
to the use of high doses of 5-FU and subsequent severe 
dose-limiting toxicity in the clinical setting.3–5 To enhance 
the concentration of anticancer molecules in the tumor 
mass while minimizing their biodistribution and toxicity, 
  nanoparticle-based drug-delivery systems are currently 
being widely investigated.6–8 Biodegradable nanocarriers 
formulated from poly(ε-caprolactone) (PCL) can protect the 
loaded antitumor drug from rapid elimination in vivo through 
metabolism, optimizing its therapeutic effect and keeping its 
associated toxicity to a minimum.9–11
The combination of chemotherapeutic agents with gene 
therapy (combined therapy) is an attractive strategy to over-
come the limitations of conventional cancer treatment. Sui-
cide gene therapy, either alone or in combination with tumor 
irradiation or chemotherapy, has been investigated for the 
treatment of intractable cancers.12 However, in colon cancer, 
gene therapy in combination with cytosine deaminase/  5-
  fluorocytosine (CD/5-FC) and herpes simplex virus thy-
midine kinase (HSV-tk), the two most widely used suicide 
prodrug systems, has obtained only limited results. In this 
context, therapeutic genes that encode cytotoxic proteins 
may provide alternatives to classical suicide-gene therapy. 
The products of these genes do not depend on prodrugs and 
may act by killing both quiescent and rapidly dividing tumor 
cells, possibly by inducing tumor cell apoptosis. Apoptosis 
deficiency is a critical factor in colorectal cancer therapy 
failure13,14 and the development of gene therapy strategies that 
improve apoptosis may therefore provide a complementary 
strategy for the treatment of colon cancer.
Toxic genes from noneukaryotic organisms such us 
bacteria, plants, viruses, and bacteriophages are being widely 
used in cancer gene therapy.15–17 The lysis gene from phage 
φX174 (gene E) has recently shown antiproliferative activity 
in cancer cells.18 The E protein (91 aa) has no detectable cell-
wall degrading activity, and its primary structure does not 
suggest any important enzymatic activity. However, electron 
microscopy images of cells undergoing E-mediated lysis 
have shown discrete 50–200 nm holes in the cell membrane. 
This observation has led to a proposed model in which the 
E protein oligomerizes to form a transmembrane tunnel 
that spans the entire cell envelope, thereby releasing the 
cytoplasmic contents.19
In this study, we investigated a new antitumor strategy 
for the treatment of colon cancer that combines 5-FU-
loaded nanoparticles (NPs) with gene therapy using gene E. 
We tested this approach using a SW480 human adenocarci-
noma colon cancer cell line that is resistant to both apoptosis 
and chemotherapy.
Materials and methods
Materials
All chemicals used, except for 5-FU, poly(ε-caprolactone) 
and Pluronic® F-68 (Sigma-Aldrich, Munich, Germany), 
were of analytical quality and were obtained from Panreac 
(Barcelona, Spain). The pcDNA3.1/GFP and pcDNA3.1-
TOPO plasmids and the DH5α chemically competent Escher-
ichia coli were purchased from Invitrogen (Carlsbad, CA). 
The pTRE plasmid (Tet-Off gene-expression system) was 
obtained from Clontech Laboratories, Inc, (Mountain View, 
CA). Gene E was kindly provided by Dr Ramos (Zaidín 
Experimental Station, CSIC, Granada, Spain).
Synthesis and characterization  
of PCL NPs
PCL NPs were prepared using the interfacial polymer 
disposition method.11,20 Briefly, 200 mg of polymer was 
dissolved in 10 mL of dichloromethane under mechanical 
stirring (300 rpm). The resulting organic solution was 
transferred dropwise into 0.05 L of a 2% (w/v) aqueous 
solution of Pluronic® F-68 stirred at 1200 rpm. The organic 
phase was then completely evaporated using a Büchi 
Rotavapor® (Büchi, Flawil, Switzerland) rotary evaporator 
to obtain an aqueous suspension of pure PCL NPs. These 
were then cleaned using repeated cycles of centrifugation 
(45 minutes at 10,000 rpm, Centrikon T-124 high-speed 
centrifuge; Kontron, Paris, France) and resuspension 
in water, until the conductivity of the supernatant 
was #10 µS/cm.
Pure PCL NPs were loaded with 5-FU using an entrapment 
procedure. The method for drug absorption onto the NPs was 
similar to that described above except that the aqueous phase 
contained appropriate amounts of the chemotherapy agent. 
The influence of the concentration of stabilizing agent and 
polymer on drug absorption was also studied. Thus, the 
amount of polymer added to the organic solution was varied 
from 0.2 to 1 g, and the concentration of stabilizing agent in 
the aqueous phase was varied between 0 and 2% (w/v). The 
production performance (yield, %) of all the formulation 
conditions was also determined:
Yield
Amountof drug loadedN Ps
Sumof materialsusedinthesynt
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The mean particle size was determined by photon 
correlation spectroscopy (PCS; Malvern Autosizer® 4700; 
Malvern Instruments Ltd, Malvern, UK), at 25.0°C ± 0.5°C. 
The scattering angle was set at 60°, and after suitable dilu-
tion of the NP suspensions (≈0.1%, w/v) measurements 
were taken in triplicate. The stability of the formulations was 
evaluated by measuring the size of the NPs after 2 weeks of 
storage at 4.0°C ± 0.5°C in water. In addition to the mean 
diameter, the system reported a polydispersity index with a 
value between 0 and 1. A polydispersity index of 1 indicated 
great differences in particle size. On the opposite, a reported 
value of 0 means that size variation is absent.
To corroborate the size determinations and to elucidate 
the shape of the NPs, nanoformulations were checked through 
analysis by Zeiss DSM 950 scanning electron micros-
copy (Carl Zeiss, Oberkochen, Germany), and by STEM 
CM20 high resolution transmission electron microscopy 
(Philips, Amsterdam, The Netherlands). Prior to observa-
tion, dilute suspensions (≈0.1%, w/v) were sonicated for 
5 minutes, and drops were placed on copper grids with 
Formvar film. The grids were then dried at 25.0°C ± 0.5°C 
in a convection oven.
The stability of the formulations was evaluated by 
measuring both the size and 5-FU loading values after 
2 weeks of storage at 4.0°C ± 0.5°C in water. To that aim, 
the International Conference on Harmonisation guidelines 
were followed.21 The electrokinetic properties of the blank 
(nonloaded) and drug-loaded NPs (≈0.1%, w/v) were ana-
lyzed by electrophoresis measurements in deionized and 
filtered water (Milli-Q Academic, Millipore, France), using 
a Malvern Zetasizer 2000 electrophoresis device (Malvern 
Instruments Ltd,). These measurements were performed after 
24 hours of contact of NPs in water under mechanical stirring 
(50 rpm) at 25.0°C ± 0.5°C. The experimental uncertainty 
of the measurements was below 5%. The theory of O’Brien 
and White was used to convert the electrophoretic mobility 
(ue) into zeta potential (ζ) values.22
Analysis of the ability of PCL NPs  
to act as 5-FU nanocarriers: drugloading 
and in vitro release studies
To determine the 5-FU concentration in all the systems 
investigated, UV absorption measurements were performed at 
the maximum absorbance wavelength (266 nm) in a   UV-Vis 
Dinko spectrophotometer (Dinko, Barcelona, Spain), with 
samples contained in quartz cells with 1 cm path lengths. 
Good linearity was observed at this wavelength, and the 
method was validated and verified for accuracy, precision 
and linearity under all conditions tested.
The loading of 5-FU onto the NPs was evaluated in 
triplicate by spectrophotometric determination of the drug 
remaining in the aqueous solution obtained upon filtration 
of the NP suspension through a membrane filter (pore size: 
0.1 µm), which was deduced from the total amount of 5-FU 
in the NP suspension. For the method to be accurate, we 
took into account the contribution of sources of absorbance 
other than the drug, for example, the surfactant agent. This 
contribution was calculated by measuring the absorbance 
of the supernatant produced under the same conditions but 
without the chemotherapy agent. The incorporation of 5-FU 
into PCL NPs was expressed in terms of 5-FU entrapment 
efficiency (%) (encapsulated drug [mg]/total drug in the NP 
suspension [mg] × 100), and 5-FU loading (%) (encapsulated 
drug [mg]/carrier [mg] × 100).
Release of 5-FU from the NPs was studied using 
  formulations prepared under optimal drugloading   conditions 
of antitumor molecules fixed into the aqueous phase at a 
concentration of 10 mM. 5-FU release in vitro was   studied in 
triplicate following the dialysis bag method, with phosphate-
buffered saline (PBS; pH 7.4 ± 0.1) as the release medium. 
The bags were first soaked in water at 25.0°C ± 0.5°C for 12 h 
before use. The dialysis bag (cut-off of Spectra/Por® 6, 2 kD 
dialysis membrane tubing; Spectrum, New Brunswick, NJ) 
retained the NPs but allowed the free anticancer   molecules 
to diffuse into the dissolution medium. A 2 mL sample of the 
NP suspension (containing the antitumor drug at 1.3 mg/mL) 
was placed into the dialysis bag with the two ends fixed 
by clamps. The bags were then placed in a glass beaker 
containing 0.2 L of the dissolution medium and stirred at 
200 rpm. The temperature was maintained at 37.0°C ± 0.5°C 
during the drug-release experiments. At preset time intervals 
(0.25, 0.5, 1, 2, 3, 6, 9, 12, 24, 48, 72, and 96 hours), 1 mL 
of the medium was withdrawn and its 5-FU content analyzed 
by UV-Vis spectrophotometry (266 nm). An equal volume 
of PBS maintained at the same temperature was added after 
sample withdrawal to ensure sink conditions. The same 
analytical procedure used to estimate the drug loading was 
followed in this investigation.
Plasmid construction for E gene 
expression
The E gene was amplified from pMC22 by polymerase 
chain reaction (PCR) using primers with EcoRI and NheI 
sites incorporated (forward, 5′-GAATTCGATGGTACG
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CTGGACTTTG-3′; reverse, 5′-CCGGGCTAGCCATT
ACATCACTCCTTCCGC-3′). Cycling conditions were: 
94°C for 1 minute, 30 cycles at 94°C for 1 minute, 65°C for 
90   seconds, 72°C for 90 seconds, and 72°C for 10 minutes. 
The amplified product and pTRE were each digested with 
EcoRI and NheI and ligated with T4 ligase to obtain pTRE-E. 
To determine the intracellular localization of the E product, 
a GFP-E gene fusion was generated. Gene E was engineered 
to eliminate the stop codon. The amplified product was 
ligated into pcDNA3.1/GFP (Invitrogen) following the manu-
facturer’s protocol, to obtain pcDNA3.1/GFP-E. Finally, the 
E gene was also subcloned into pcDNA3.1-TOPO to obtain 
pcDNA3.1/E. Subcloning-efficiency DH5α E. coli were 
transformed with the generated plasmids and their correct 
sequences were confirmed by DNA sequencing.
Cell culture and drugs
The simple (ie, 5-FU-loaded PCL NPs and gene E therapy 
administered separately) and combined treatments were 
tested in the apoptosis- and chemoresistant SW480 human 
carcinoma cell line (Instrumentation Service Center, Granada 
University, Granada, Spain).23 Cells were grown in RPMI 
1640 medium (Sigma, St Louis, MO), supplemented with 
10% fetal bovine serum (FBS), 15 mM HEPES, 14 mM 
NaHCO3, 2 mM l-glutamine, 40 µg/mL gentamicin, and 
500 µg/mL ampicillin (Antibióticos S.A, Madrid, Spain). 
Cells were maintained in monolayer culture at 37°C in an 
atmosphere containing 5% CO2.
Production and selection of stable 
inducible SW480 cell clones
To analyze E gene activity against colon cancer, SW480 cells 
were transfected with pTRE-E using the Fugene 6 DNA 
transfection reagent (Roche, Madrid, Spain). Cells were 
initially transfected with pTet-On and successfully-
transfected clones were selected for geneticin (1 mg/mL) 
resistance and rtTA expression. Clones were then transfected 
with pTRE-E, a pTRE2hyg vector containing the E cDNA 
and selected for resistance to geneticin (1 mg/mL) and 
hygrovodamycin (0.4 mg/mL). Two of the four clones 
identified in the first transfection round were used in a 
second round of transfections with the pTRE-E expression 
plasmid to give a total of 12 derivative clones. All clones 
were cultured in the presence of doxycycline (Dox; 
0.2 mg/mL, 24 hours) to induce E gene expression, which 
was detected by reverse transcriptase (RT)-PCR. cDNA was 
generated using the Promega Reverse Transcription System 
(Promega, Madrid, Spain) using 1 µg of total RNA (Rneasy 
Mini kit; Qiagen, Hilden, Germany). PCR amplification 
of the E gene was then performed using specific primers 
(forward, 5′-GCTTTCCTGCTCCTGTTGAG-3′; reverse, 
5′-TTGACGCACGTTTTCTTCTG-3′) under the following 
conditions: 94°C for 1 minute, 35 cycles at 94°C for 
1 minute, 55°C for 30 seconds, 72°C for 30 seconds, 
and 72°C for 10 minutes. Amplification of β-actin 
(forward, 5′-ATCATGTTTGAGACCTTCAA-3′; reverse, 
5′-CATCTCTTGCTCGAAGTCCA-3′) was used to assess 
RNA integrity. Amplified PCR products were visualized by 
agarose gel electrophoresis and quantified using a Bio-Rad 
documentation system (Quantity One Analysis software; 
Bio-Rad Laboratories, Hercules, CA). Relative E expression 
was calculated as the ratio of E to β-actin. One transfected 
clone, SW480/12/E, presented significant gene E expression 
in the presence of Dox with no background expression, and 
was used to test the simple and combined treatments.
Proliferation assays
The antitumor effect of the 5-FU-loaded NPs, E gene therapy, 
and the combined treatment schedule was evaluated using 
the proliferation assay. Cells were seeded in a 96-well plate 
(6 × 103 cells per well). At different times, 20 µL of 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
solution (5 mg/mL) was added to each well followed by 
incubation at 37°C for 4 hours. The medium was removed 
and 200 µL of dimethyl sulfoxide (DMSO) was added to 
each well. The optical density (OD) at 570 and 690 nm was 
determined using a Titertek multiscan colorimeter (Flow, 
Irvine, CA). To determine the percentage of relative cell 
viability (%RCV) we used the formula %RCV = (treated cells 
OD/untreated cells OD) × 100. In addition, the MTT assay 
was used to determine the cytotoxicity of the 5-FU-loaded 
NPs at a wide range of concentrations (10–200 mM).
Apoptosis analysis
Cells were harvested, washed two times with sample buffer 
(100 mg glucose; 100 mL PBS without Ca2+ or Mg2+) and 
fixed in 70% (v/v) cold ethanol for 1 hour before staining. 
The cells were pelleted and resuspended in a solution 
containing 50 µg/mL propidium iodide (PI) and 0.5 mg/mL 
RNase in sample buffer at pH 7.4, for 30 minutes in the dark. 
Apoptosis was evaluated using a fluorescence-activated cell-
sorter flow cytometer (Becton Dickinson, Franklin Lakes, 
NJ) and all data were analyzed using the Cellfit program. 
To determine possible caspase activation during E gene 
expression, a sample of transfected cells was preincubated 
in the pan caspase inhibitor zVAD-fmk (BD Pharmingen, 
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San Jose, CA) at 200 mM, 2 hours before the induction of 
E gene expression.
Fluorescent microscopy analysis  
of E protein localization
SW480 cells were transfected with pcDNA3.1/GFP-E using 
Fugene 6 (Roche), as described above, to determine the intrac-
ellular localization of the E protein. For mitochondrial staining, 
the medium was changed to DMEM containing 500 nM 
MitoFluor Red (MitoTracker; Invitrogen, Barcelona, Spain), 
incubated for 15 minutes, and then replaced with normal 
medium. For nuclear staining, 1 mL of DAPI (Invitrogen) at 
100 nM was added to fixed cells in a 60 mm dish, and incubated 
for 20 minutes at room temperature. The cells were then rinsed 
with PBS and mounted. GFP was excited at 488 nm, DAPI 
nuclear stain at 364 nm, and MitoFluor Far Red at 588 nm. 
Fluorescent microscopy analysis was carried out using a Nikon 
Eclipse Ti (Nikon Instruments Inc, Melville, NY).
Measurement of the mitochondrial 
membrane potential (∆Ψm) and the 
caspase activation
To measure levels of ∆Ψm disruption, cells were washed 
twice with cold PBS and incubated with 40 nM DiOC6(3) 
(Invitrogen) for 15 minutes at 37°C. Cells were then washed 
with ice-cold PBS and resuspended in 500 µL of PBS. The 
fluorescence intensities of DiOC6(3) were analyzed using 
a FACScan flow cytometer with excitation and emission 
  settings of 484 and 500 nm, respectively. Caspase activation 
was evaluated by western blot analysis using 30 µg of cell 
protein extract separated by SDS-PAGE (Mini Protean II 
cell; Bio-Rad Laboratories) and transferred to a nitrocellulose 
membrane (20 V at room temperature for 30 min). The 
blots were treated with blocking solution (20 mM Tris, 
0.9 NaCl, 10% nonfat milk) for 3 hours and then incubated 
with   primary rabbit polyclonal IgG anti-caspase-3 (1:1000 
dilution), anticaspase-8 (1:200 dilution), anti-caspase-9 
(1:500 dilution) and anti-β-actin antibodies (1:5000 dilution; 
Abcam, Cambridge, MA) overnight at 4°C. After addition of 
the peroxidase-conjugated secondary antibody, the   proteins 
were detected by enhanced chemiluminescence (ECL; Bonus, 
Amersham, Little Chalfont, UK). A protein extract from 
transfected cells treated with zVAD-fmk as described above 
was also included in the study.
Morphological analysis
Cells were analyzed by optical and transmission elec-
tronic microscopy (Hitachi H7000 transmission electron 
microscope; Hitachi, Tokyo, Japan) according to Prados 
and colleagues.24
Statistical analysis
The SPSS software package (v. 14; SPSS Inc, Chicago, IL) was 
used for all statistical analyses. Results were compared using 
Student’s t-test. All data were expressed as means ± standard 
deviations of sample means. Differences were considered 
statistically significant at a P value ,0.05.
Results and discussion
Particle geometry, surface charge,  
and stability
The interfacial polymer disposition method allowed the 
formation of well-stabilized spherical PCL NPs with 
an average diameter of 140 ± 20 nm and a narrow size 
distribution (polydispersity index: 0.046) (Figure 1). 
No presence of aggregates or bulky sediments was observed. 
The size of the polymeric particles and the quality of the 
suspensions did not vary significantly when loaded with 
different amounts of 5-FU (Table 1). This particle size 
could be considered as particularly suitable for facilitating 
the cellular uptake of the nanomedicine; it is assumed that 
NPs with a diameter in the range 100–200 nm can easily 
be internalized by receptor-mediated endocytosis, whereas 
larger particles are generally taken up by phagocytosis.25 
Given an appropriate cellular uptake of PCL NPs with a mean 
diameter of 140 nm ± 20 nm, a significant enhancement of 
the 5-FU concentration in tumor cells might be expected. No 
antitumor drug release and/or precipitation, NP aggregation 
or change in the size of particles was detected after two 
weeks of storage at 4.0°C ± 0.5°C in water. Thus, if the 
nanoparticulate preparations were not used immediately 
AB
Figure  1  Scanning  electron  microscope  (A)  and  high  resolution  transmission 
electron microscope (B) images of PCL NPs. 
Note: All scale bars shown in the figure are 150 nm. 
Abbreviations: NPs, nanoparticles; PCL, poly(ε-caprolactone).
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after formulation, they were kept under the aforementioned 
storage conditions until use.
The zeta potential values of the nonloaded and 5-FU-
loaded PCL NPs in deionized and filtered water were found 
to be −18.3 ± 0.4 and −19.1 ± 0.6 mV , respectively. Such data 
clearly shows how similar are the surface electrical charges 
of these NPs which points out that the antitumor agent was 
not adsorbed onto the polymeric surface. Consequently, a 
very efficient drug entrapment has led to 5-FU-loaded PCL 
NPs which, from an electrokinetic point of view, are indis-
tinguishable from nonloaded PCL.
Analysis of the capabilities of PCL NPs  
as 5-FU nanocarriers: drug loading  
and in vitro release studies
It is possible that 5-FU loading onto PCL NPs benefit 
from electrostatic attractive forces that may exist between the 
positively charged drug molecules (generated by protonation 
of the NH group of the 5-FU chemical structure),26 and the 
negatively charged polymeric NPs.11 While this might be the 
case, we attempted to improve drug loading by introducing 
the 5-FU molecules before the interfacial polymer disposition 
process to induce mechanical drug   trapping. Furthermore, 
a stabilizing agent (Pluronic® F-68) was added to facilitate 
the opening of the polymeric chains and to yield a noncom-
pact structure into which 5-FU could be incorporated.11,27 
Figure 2A shows the entrapment efficiency (%) and loading 
(%) of 5-FU onto the PCL NPs as a function of drug con-
centration. This figure indicates that the 5-FU concentration 
positively affects the entrapment efficiency. An initial drug 
concentration of 10–4 M in the entrapment medium gave 
entrapment efficiency and loading values of 4.7% ± 0.9% 
and 0.015% ± 0.003%, respectively, while one of 10–2 M gave 
entrapment efficiency and loading values of 34.5% ± 3.3% 
and 11.219% ± 1.074%, respectively.
Table 2 shows the influence of the Pluronic® F-68 and 
PCL concentrations used in the formulation of the NPs on 
5-FU loading (%). Drug loading was markedly lower in the 
absence of the surfactant agent, but increased considerably 
and remained unaltered at and above 0.5% (w/v) Pluronic® 
F-68 in the concentration range tested. Interestingly, the yield 
of 5-FU-loaded polymeric NPs was always higher than 94% 
in all formulations tested with surfactant agent, but decreased 
Table 1 Influence of 5-FU loading (%) on size of PCL NPs
5-FU loading (%) Size (nm)
0 140 ± 20
0.015 ± 0.003 135 ± 25
0.252 ± 0.023 120 ± 20
0.709 ± 0.075 140 ± 30
4.829 ± 0.342 125 ± 30
11.219 ± 1.074 150 ± 25
Abbreviations: 5-FU, 5-fluorouracil; NPs, nanoparticles; PCL, poly(ε-caprolactone).
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Figure  2  5-FU  loading  and  in  vitro  release  studies.  (A)  Efficiency  of  5-FU 
entrapment (%) into PCL NPs as a function of antitumor drug concentration (inset: 
corresponding 5-FU loading values, %). The lines are guides for the eye and have 
no other significance. (B) 5-FU release (%) from PCL NPs at 37.0°C ± 0.5°C as a 
function of incubation time in PBS (pH 7.4 ± 0.1). 
Abbreviations: 5-FU, 5-fluorouracil; NPs, nanoparticles; PBS, phosphate-buffered 
saline; PCL, poly(ε-caprolactone).
Table  2  Influence  of  PCL  and  Pluronic®  F-68  concentration 
on  5-FU  entrapment  efficiency  (%)  and  5-FU  loading  (%)  by 
entrapment into the polymeric NP network
PCL 
(%, w/v)
Pluronic® F-68 
(%, w/v)
5-FU entrapment 
efficiency (%)
5-FU loading (%)
0.5 1 32.7 ± 2.8 10.634 ± 0.911
1 1 34.5 ± 3.3 11.219 ± 1.074
2 1 33.1 ± 1.9 10.764 ± 0.618
1 0 4.3 ± 0.4 1.398 ± 0.127
1 0.5 35.2 ± 3.1 11.447 ± 1.009
1 2 34.7 ± 2.6 11.284 ± 0.846
Note: The NPs were synthesized into an aqueous solution containing 10–2 M of 
antitumor molecules.
Abbreviations: 5-FU, 5-fluorouracil; NPs, nanoparticles; PCL, poly(ε-caprolactone).
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to below 9% in the absence of this macromolecule. It can 
therefore be assumed that smaller polymeric NPs with a 
narrower size distribution were obtained after addition of 
the surfactant to the aqueous solution, without influencing 
the drug incorporation into the polymer. Similarly, the PCL 
concentration did not significantly influence drug loading 
onto the NPs.
5-FU release from the polymeric matrix followed a 
  biphasic process typical of PCL at pH 7.4,11,20,28 with an 
initial fast drug release (up to ≈ 27% in 3 hours) and the 
remaining 5-FU being released in a sustained manner over 
a further period of 93 hours (Figure 2B). The initial fast 
5-FU release is attributed to the leakage of surface-bound 
and/or poorly entrapped drug, which rapidly diffused 
into the incubation medium. It is likely that the sustained 
release phase   corresponds to the 5-FU fraction (ie, ≈ 73%) 
that was deeply embedded into the polymeric nanomatrix, 
which must follow a longer diffusion path before leakage. 
This suggests that the majority of the 5-FU was entrapped 
in the polymeric network rather than being adsorbed onto 
the NP surface.
Antitumor activity of 5-FU-loaded  
PCL NPs on SW480 cells
We initiated this investigation with an analysis of the 
cytotoxic activity of blank (nondrug-loaded) PCL NPs 
on SW480 human adenocarcinoma colon cancer cells. 
As shown in Figure 3A, the MTT assay results indicate 
that there were no significant differences between the 
absorbance of the negative control and the wells treated with 
blank NPs after incubation for 72 hours (P . 0.05). Thus, 
PCL NPs show no cytotoxicity and may be considered to be 
appropriate for drug-delivery purposes. We then compared 
the ability of 5-FU and 5-FU-loaded PCL NPs to inhibit the 
proliferation of SW480 cells. These cells have an inherent 
resistance to apoptosis that correlates with chemoresis-
tance to 5-FU23 and, along with cell lines SW620, HCT-8 
and DLD1/5FU, are amongst the most resistant colon cell 
lines to this drug.29 This is of interest given the relationship 
between colon cancer drug resistance and invasive/meta-
static ability.30 The nanomedicine inhibited cell prolifera-
tion in a dose-dependent manner with a much lower IC50 
(concentrations of the drug needed to reduce population 
growth by 50% in vitro) value (0.1 µM) than that reported 
previously for SW480 cells (IC50 5-FU: 4 µM),31 show-
ing that the antitumor effect of 5-FU-loaded PCL NPs 
in SW480 was 40-fold higher than that for the free drug 
(Figure 3B).
Antitumor activity of gene E  
on SW480 cells
The stable SW480/12/E clone was used to determine the 
antitumor activity of gene E in apoptosis-resistant colon 
cancer cells. Cultivation of these cells in the presence of 
Dox showed effective expression of the E gene compared 
to the same cells without Dox. Analysis of RT-PCR 
products amplified from gene E cDNA, normalized to the 
corresponding β-actin signal, showed a slight time-dependent 
increase in E expression (2- and 2.7-fold higher at 48 and 
72 hours versus cells at 24 hours; Figure 4A). Cells showed 
a corresponding significant and time-dependent decrease in 
viability (30.5%, 41.9%, and 70.4% at 24, 48, and 72 hours, 
respectively; Figure 4B).
Most colon cancer gene therapy assays investigated 
to date have used a prodrug therapy system in which the 
anticancer molecule is activated by exogenous genes that 
encode enzymes, such as HSV-tk and CD. However, assays 
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in which either of these enzymes were used produced only 
limited results.32–34 The use of specific promoters, such us the 
promoter of Cox-2 or uPAR, improves its tissue specificity 
but not its efficacy.27,35 Recently, Lee and colleagues36 used 
a combination of shMDR and HSV1-tk to significantly 
decrease (63.3%) the volume of tumors generated in mice 
by HCT-15 colon cancer cells. However, prodrugs continue 
to be one of the main limiting factors of these strategies.37 
In this context, the transfection of cDNA constructs that 
encode toxins with direct antitumor activities represents 
a good alternative. These toxin genes have been success-
fully used in pancreatic cancer (diphtheria toxin gene),15 
hepatocellular carcinoma (staphylococcal enterotoxin 
C2),38 breast and prostate cancer (Clostridium perfringens 
enterotoxin and Pseudomonas aeruginosa exotoxin A),39 
and breast cancer and melanoma (gef gene).40,41 Expressed 
bacteriophage genes, such as that coding for the lambda-
holin protein, have led to a substantial reduction (more 
than 98%) of cell viability in breast cancer cells.42 We have 
previously shown that E gene expression efficiently inhibits 
proliferation of melanoma and colon cancer drug-sensitive 
cells.18,43 Our present findings show that E gene expression 
is able to induce a significant antiproliferative effect in a 
drug-resistant SW480 cell line.
E gene expression induces caspase-3-  
and caspase-9-mediated apoptosis  
in SW480 cells
As shown in Figure 5A, SW480/12/E cells at 24 hours 
after induction with Dox showed an apoptosis fraction of 
41.5% ± 0.4%. This was significantly higher than that for 
the control groups (2.1% ± 0.47% for SW480/12/E and 
1.5% ± 0.32% for parental cells). After 48 and 72 hours 
of transfection, the percentage of apoptotic cells increased 
to 62.3% ± 0.52% and 85.07% ± 0.9%, respectively. These 
results show that E gene expression induces an intense 
apoptosis phenomenon in apoptosis-resistant SW480 
colon cancer cells (85.07% at 72 hours). This result is 
of particular interest as apoptosis resistance is one of the 
characteristics implicated in colon cancer development and 
metastasis.30 In addition, defects in apoptotic machinery 
are a major cause of cytotoxic drug resistance.44 Although 
the mechanism underlying apoptosis resistance is not clear, 
colon cancer cells may contain high levels of antiapoptotic 
proteins (PED, cFLIP, Bcl-xL, and Bcl-2).45 Recently, it 
was shown that the gene inhibitor of apoptosis 2 (cIAP2) 
is upregulated in DLD-1/FU-resistant cells (with char-
acteristics similar to SW480, SW620, and HCT-8 cells). 
Interestingly, downregulation of cIAP2 by siRNA induced 
an efficient caspase-3-mediated apoptosis.29 Apoptosis 
induction was efficiently inhibited by zVAD-fmk in 
transfected SW480 cells (Figure 5A), suggesting the 
involvement of the mitochondrial apoptotic pathway. 
Western blot analysis confirmed caspase-9 and capase-3 
activation, whereas caspase-8 showed no modulation of 
expression (Figure 5B). Treatment of SW480/12/E cells 
with zVAD-fmk efficiently inhibited E-induced caspase-3 
and caspase-9 activation, which appeared to be at similar 
levels to that in SW480/12/E cells without Dox exposure 
(Figure 5B). E-induced modulation of apoptosis may there-
fore be a promising new strategy in colon cancer treatment, 
especially in those that exhibit apoptosis resistance.
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methods) SW480 cells without transfect reagents were used as control. Data are 
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cells after 48 hours, when cells were swollen, and after 
72 hours, when the number of spherical cells increased rap-
idly   (Figure 5). As shown in Figure 7A, a significant decrease 
in ∆Ψm was detected in SW480/12/E cells induced with Dox 
at 24, 48, and 72 hours in comparison with SW480/12/E 
cells not exposed to Dox, or SW480 parental cells (data not 
shown). This decrease in fluorescence intensity reflects the 
E gene-induced depolarization of the inner mitochondrial 
membrane, and defines an early, but already irreversible, 
stage of apoptosis.
To further investigate the nature of E gene-mediated 
cytotoxicity, SW480/12/E cells were analyzed by transmis-
sion electron microscopy. The most significant morphological 
change in the SW480/12/E cells induced with Dox was the pro-
nounced swelling of the mitochondria, which showed disrupted 
cristae after 24 hours of treatment (Figure 7B (b) and (c)). The 
mitochondria in noninduced cells remained unaffected. In some 
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Figure 5 Apoptosis signals after E gene expression in SW480 cells. (A) SW480/12/E 
cells before and after Dox induction at times indicated were analyzed by FACScan to 
determine apoptotic cell death. The apoptosis was assessed after propidium iodine 
staining by calculating the percentage of cells in the sub-G1 fraction. SW480/12/E cells 
treated with zVAD-fmk were also analyzed at 72 hours. SW480 parental cells were 
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experiments. (B) Activated (cleaved) caspase-3, caspase-9, and pro-caspase-8 were 
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Abbreviation: Dox, doxorubicin.
E protein is located in the mitochondria, 
induces the loss of mitochondrial 
membrane potential, and changes the cell 
morphology of SW480 cells
SW480 cells transfected with pcDNA3.1/GFP-E were 
used to determine the mitochondrial localization of E pro-
tein.   Immunofluorescence microscopy produced a merged 
image with yellow regions where green (GFP-E) and red 
(  MitoFluor) fluorescence overlap (Figure 6). Significant 
morphological changes were observed in the transfected 
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Figure 6 Mitochondrial localization of the GFP/E fusion protein in SW480 cells. 
Representative fluorescent microscopy images of transfected SW480 cells expressing 
fusion protein E-GFP at 24 (×10), 48 (×40), and 72 hours (×40). The dotted pattern 
of GFP-E fluorescence is shown in green. The majority of expressed GFP-E was 
found to be colocalized with MitoFluor (shown in red color). Colocalization is 
shown in yellow. Cell nuclei were counterstained with DAPI.
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cases, significant accumulations of intermediate   filaments were 
also observed around the nucleus (Figure 7B (d)), along with 
a dilated endoplasmic reticulum (Figure 7B (e)), although this 
was not always the case.
Effect of the combined use of  
5-FU-loaded PCL NPs and the cytotoxic 
suicide gene E on SW480 cancer cells
After independently establishing the effect of 5-FU-loaded 
PCL NPs and E gene on the SW480 colon cancer cells, we 
investigated the antitumor effect of the combined treatments. 
The modulation of cell proliferation was determined at 6, 12, 
and 24 hours. Treatment with both 5-FU-loaded PCL NPs and 
with Dox (to induce E gene expression) produced a decrease in 
viability of SW480/12/E cells of 87% ± 3.1%. This is greater 
than the sum of the effects of separate treatments with 5-FU PCL 
NPs (40.8% ± 2.6%) and E gene expression (30.5% ± 1.8%), 
suggesting a synergistic antitumor effect. Treatment with free 
5-FU and E gene expression in SW480/12/E cells resulted 
in a much lower synergistic effect than that of 5-FU-loaded 
PCL NPs and E gene expression (Figure 8A). Furthermore, 
this combined therapy (5-FU-loaded PCL NPs and E gene 
expression) in SW480/12/E cells induced an increase in the 
percentage of apoptotic cells at 24 hours (83% ± 4.6%) greater 
than that obtained from the independent use of 5-FU-loaded 
PCL NPs and E gene expression (22% ± 2.5% and 41% ± 5%, 
respectively), suggesting the combined use of these treatments 
has an important enhancement of the apoptotic effect in this 
resistant tumor cell line (Figure 8B).
Novel advances in the use of combined therapy for the 
treatment of lung,46 bladder,47 pancreatic,48 and hepatocel-
lular cancer,49 have been reported. In colon cancer, Abaza 
and colleagues50 have recently demonstrated that antisense 
c-myc in combination with cytotoxic drugs (including 5-FU) 
increased caspase-3 (amongst other apoptotic signals) and 
exhibited a marked apoptotic effect compared to each com-
ponent treatment alone. Our objective, to explore the ability 
of the E gene to enhance the cytotoxic effect of drugs against 
colon cancer cells, was similar. In light of previous results 
obtained with 5-FU-loaded PCL NPs against SW480 cells, 
we assayed a combined therapy involving 5-FU-loaded PCL 
NPs and cytotoxic E suicide gene expression, and found it 
to induce a decrease in SW480 cell viability around 20% 
greater than the sum of the individual treatments. This find-
ing supports the hypothesis that a synergistic effect occurs 
when both treatments are administered together.
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Figure 7 Mitochondrial damage caused by E protein in SW480 cells. (A) SW480 
parental cells and SW480/12/E before and 24, 48, and 72 hours after Dox induction 
were  stained  with  DiOC6,  and  analyzed  by  flow  cytometry  to  determine  the 
mitochondrial membrane potential (∆Ψm) disruption caused by E gene expression. 
Data  shown  are  representative  results  from  four  independent  experiments.   
(B) Ultrastructural analysis showed that the morphology of SW480/12/E cells not 
induced by Dox was similar to that of SW480 parental cells, with a typical presence 
of  a  large  nucleus  and  light  cytoplasmic  complexion  containing  well-preserved 
organelles  including  mitochondria  (a,  2000×).  In  contrast,  E  gene  expression  in 
SW480/12/E after Dox exposure generated a large number of altered mitochondria 
with disrupted cristae (b, 6000×). These cells eventually presented noticeably dilated 
mitochondria (c, 12,000×). Furthermore, mitochondrial changes in some cells were 
accompanied by the presence of dilated smooth endoplasmic reticulum (d, 9000×), 
and the presence of clusters of intermediate filaments (e, 4000×).
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Conclusion
We have described the most advantageous synthetic 
conditions for producing 5-FU-loaded PCL NPs. 5-FU 
entrapment into the polymeric NPs has resulted in important 
drug loading and sustained drug-release properties, thereby 
opening up opportunities for improved delivery of 5-FU to 
cancer cells. 5-FU PCL NPs exhibited a 40 times greater in 
vitro antitumor activity than free 5-FU. Furthermore, the 
utility of E gene expression for the induction of growth arrest 
in colon cancer cells with an apoptosis-resistant phenotype 
was analyzed. E gene expression was found to strongly 
induce apoptosis mediated by the mitochondrial pathway 
in these resistant cells, and to significantly enhance the cell 
growth inhibition induced by 5-FU-loaded PCL NPs. These 
results suggest that this combined antitumor strategy may 
be a   promising therapy in patients with advanced-stage 
colon cancer. Future studies will, however, be necessary to 
determine its in vivo utility.
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